For the first time in Africa, a Senegalese laboratory is producing generic hydroxyurea, the gold standard in sickle cell treatment with the hopes of providing cheaper treatment medication.

Africa accounts for nearly 80 per cent of cases of the inherited red blood cell disorder but has relied on expensive imported medication.

For the first time in Africa, a Senegalese laboratory is producing generic hydroxyurea, the gold standard in sickle cell treatment with the hopes of providing cheaper treatment…